416 related articles for article (PubMed ID: 28622731)
21. The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development.
Tagle DA
Curr Opin Pharmacol; 2019 Oct; 48():146-154. PubMed ID: 31622895
[TBL] [Abstract][Full Text] [Related]
22. Liver microphysiological platforms for drug metabolism applications.
Kulsharova G; Kurmangaliyeva A
Cell Prolif; 2021 Sep; 54(9):e13099. PubMed ID: 34291515
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in Organ-on-Chips Integrated with Bioprinting Technologies for Drug Screening.
Tabatabaei Rezaei N; Kumar H; Liu H; Lee SS; Park SS; Kim K
Adv Healthc Mater; 2023 Aug; 12(20):e2203172. PubMed ID: 36971091
[TBL] [Abstract][Full Text] [Related]
24. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
25. Roadblocks confronting widespread dissemination and deployment of Organs on Chips.
Alver CG; Drabbe E; Ishahak M; Agarwal A
Nat Commun; 2024 Jun; 15(1):5118. PubMed ID: 38879554
[TBL] [Abstract][Full Text] [Related]
26. Integrating Biosensors in Organs-on-Chip Devices: A Perspective on Current Strategies to Monitor Microphysiological Systems.
Ferrari E; Palma C; Vesentini S; Occhetta P; Rasponi M
Biosensors (Basel); 2020 Aug; 10(9):. PubMed ID: 32872228
[TBL] [Abstract][Full Text] [Related]
27. Tackling rare diseases: Clinical trials on chips.
Blumenrath SH; Lee BY; Low L; Prithviraj R; Tagle D
Exp Biol Med (Maywood); 2020 Jul; 245(13):1155-1162. PubMed ID: 32397761
[TBL] [Abstract][Full Text] [Related]
28. Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.
Kopec AK; Yokokawa R; Khan N; Horii I; Finley JE; Bono CP; Donovan C; Roy J; Harney J; Burdick AD; Jessen B; Lu S; Collinge M; Sadeghian RB; Derzi M; Tomlinson L; Burkhardt JE
J Toxicol Sci; 2021; 46(3):99-114. PubMed ID: 33642521
[TBL] [Abstract][Full Text] [Related]
29. High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.
Conant G; Lai BFL; Lu RXZ; Korolj A; Wang EY; Radisic M
Stem Cell Rev Rep; 2017 Jun; 13(3):335-346. PubMed ID: 28429185
[TBL] [Abstract][Full Text] [Related]
30. Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate).
Baran SW; Brown PC; Baudy AR; Fitzpatrick SC; Frantz C; Fullerton A; Gan J; Hardwick RN; Hillgren KM; Kopec AK; Liras JL; Mendrick DL; Nagao R; Proctor WR; Ramsden D; Ribeiro AJS; Stresser D; Sung KE; Sura R; Tetsuka K; Tomlinson L; Van Vleet T; Wagoner MP; Wang Q; Arslan SY; Yoder G; Ekert JE
ALTEX; 2022; 39(2):297–314. PubMed ID: 35064273
[TBL] [Abstract][Full Text] [Related]
31. From organ-on-chip to body-on-chip: The next generation of microfluidics platforms for in vitro drug efficacy and toxicity testing.
Lacombe J; Soldevila M; Zenhausern F
Prog Mol Biol Transl Sci; 2022; 187(1):41-91. PubMed ID: 35094781
[TBL] [Abstract][Full Text] [Related]
32. Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium.
Rusyn I; Sakolish C; Kato Y; Stephan C; Vergara L; Hewitt P; Bhaskaran V; Davis M; Hardwick RN; Ferguson SS; Stanko JP; Bajaj P; Adkins K; Sipes NS; Hunter ES; Baltazar MT; Carmichael PL; Sadh K; Becker RA
Toxicol Sci; 2022 Jul; 188(2):143-152. PubMed ID: 35689632
[TBL] [Abstract][Full Text] [Related]
33. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
34. A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies.
Phillips JA; Grandhi TSP; Davis M; Gautier JC; Hariparsad N; Keller D; Sura R; Van Vleet TR
Lab Chip; 2020 Feb; 20(3):468-476. PubMed ID: 31989145
[TBL] [Abstract][Full Text] [Related]
35. Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity.
Moon HR; Surianarayanan N; Singh T; Han B
Biomicrofluidics; 2023 Dec; 17(6):061504. PubMed ID: 38162229
[TBL] [Abstract][Full Text] [Related]
36. Maximizing the impact of microphysiological systems with in vitro-in vivo translation.
Cirit M; Stokes CL
Lab Chip; 2018 Jun; 18(13):1831-1837. PubMed ID: 29863727
[TBL] [Abstract][Full Text] [Related]
37. Introducing an automated high content confocal imaging approach for Organs-on-Chips.
Peel S; Corrigan AM; Ehrhardt B; Jang KJ; Caetano-Pinto P; Boeckeler M; Rubins JE; Kodella K; Petropolis DB; Ronxhi J; Kulkarni G; Foster AJ; Williams D; Hamilton GA; Ewart L
Lab Chip; 2019 Jan; 19(3):410-421. PubMed ID: 30663729
[TBL] [Abstract][Full Text] [Related]
38. Organs-on-chips at the frontiers of drug discovery.
Esch EW; Bahinski A; Huh D
Nat Rev Drug Discov; 2015 Apr; 14(4):248-60. PubMed ID: 25792263
[TBL] [Abstract][Full Text] [Related]
39. Evolving the Role of Discovery-focused Pathologists and Comparative Scientists in the Pharmaceutical Industry.
Mohanan S; Maguire S; Klapwijk J; Adler R; Haworth R; Clements P
Toxicol Pathol; 2019 Feb; 47(2):121-128. PubMed ID: 30651043
[TBL] [Abstract][Full Text] [Related]
40. Tissue Chips in Space: Modeling Human Diseases in Microgravity.
Low LA; Giulianotti MA
Pharm Res; 2019 Dec; 37(1):8. PubMed ID: 31848830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
